ArticleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2025
Impact of the COVID-19 Pandemic on Hospital Antimicrobial Purchasing in Canada (2018-2021): An Exploratory Analysis.
Article in Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antimicrobial Use among Adult Inpatients in Northern Canada, 2019-2021.The Canadian journal of hospital pharmacy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The impact of the COVID-19 pandemic on antimicrobial use in Canadian hospitals is not well characterized. We explored the relationship between the COVID-19 pandemic and Canadian hospital antimicrobial purchasing (AMP)-a proxy for consumption. Methods: Hospital-level AMP data were obtained from IQVIA, a health analytics company, and matched with inpatient patient-day denominator data from 28 hospitals participating in the Canadian Nosocomial Infection Surveillance Program. Monthly AMP was measured using defined daily doses (DDDs) per 1,000 patient-days. Segmented linear regression with hospital-level clustering assessed for step and slope changes in AMP between pre-pandemic (January 1, 2018 - February 29, 2020) and pandemic (March 1, 2020 - December 31, 2021) periods. Results: Although we found an initial increase in AMP with the onset of the pandemic (+42 DDDs/1,000 patient-days [pd]) followed by a decreasing trend in AMP during the pandemic (-5 DDDs/1,000 pd per month), neither was statistically significant. Changes in trends varied across antimicrobial classes/subclasses, with decreases in broad-spectrum penicillins (-2 DDDs/1,000 pd per month, Conclusions: We observed a transient increase in overall AMP with the onset of the pandemic (March 2020) in this exploratory analysis of a sample of 28 hospitals. Changes in trends varied by antimicrobial class/subclass and individual agent. Further work is needed to discern contributors to these trends, such as changes in inpatient characteristics and treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.